With this being the Thanksgiving Weekend, I had time to work on my backlog. One of the items was special studies. I have done the following changes:

• Executed the analysis for both uBiome and Thryve/Ombre samples. So more samples will have the option of using special studies.
• Implemented Consensus/Monte Carlo between the bacteria, casting the species (which are not reported consistently between labs) to their genus. These are shown on the [Key Bacteria] link below.

Last, I have added per  Peripheral neuropathy to the symptom list.

REMEMBER TO ANNOTATED YOU SAMPLES WITH YOUR SYMPTOMS

This is what Special Studies use.

Example: for Chronic Fatigue Syndrome

The page below shows a distinct pattern for ME/CFS with Bifidobacterium being the greatest significance. For this bacteria, my first suggestion is simple:  Human milk oligosaccharides (HMOs) and Bifidobacerium infantis probiotics.

• Human Milk Oligosaccharides: Health Benefits, Potential Applications in Infant Formulas, and Pharmacology [2020]
• “The results reflect the metabolic abilities of the respective bifidobacteria. B. bifidum used secretory glycosidases to degrade HMOs, whereas B. longum subsp. infantis assimilated all HMOs by incorporating them in their intact forms.” [2011]

It is interesting to note that Lactobacillus does not appear as significant.

Bottom Line

Special Studies are still a “work-in-progress”. Using them “as is” have not produced superior results to those from the standard triplet (Outside Lab Range, Box-Plot-Whiskers, Kaltoft-Moldrup) — see this post for an example. How do I determine which is better? For ME/CFS, we should have the top suggested items being cross validated with clinical studies. Feel free to explore the results.

I will continue working on getting superior results from special studies — stay tune!